Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA6 | P23280 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370668 | 1.00 | KMT2A (0.70) | KMT2AMEN1CA2CA1MMP1 | |
| Hydrochloric Acid SCHEMBL28910568 | 0.98 | KMT2A (0.68) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL29889311 | 0.98 | KMT2A (0.68) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL22719534 | 0.98 | KMT2A (0.68) | KMT2AMEN1CA2CA1MMP1 | |
| Acetic Acid SCHEMBL29097243 | 0.89 | KMT2A (0.58) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL30648996 | 0.86 | KMT2A (0.63) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL2039879 | 0.83 | KMT2A (1.00) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL11566827 | 0.83 | KMT2A (1.00) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL30446303 | 0.83 | KMT2A (1.00) | KMT2AMEN1CA2CA1MMP1 | |
| SCHEMBL7531976 | 0.82 | KMT2A (0.53) | KMT2AMEN1CA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576029-B2 | Noncompetitive receptor-targeted vaccine delivery to plasmacytoid dendritic cells | WASHINGTON UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025053947-A1 | SYNTHETIC TRITERPENES COMPOSITION, METHOD OF PRODUCTION AND APPLICATIONS THEREOF | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024081775-A1 | SYNTHESIS OF 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20240024238-A1 | NONCOMPETITIVE RECEPTOR-TARGETED VACCINE DELIVERY TO PLASMACYTOID DENDRITIC CELLS | WASHINGTON UNIVERSITY ST LOUIS (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4291328-A1 | DIRUTHENIUM CATALYST COMPOSITIONS AND SYNTHETIC PROCESSES RELATED THERETO | Emory University (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-20130252341-A1 | METHOD AND DEVICE FOR DETECTING NUCLEIC ACID, AND KIT | KANEKA CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-2620508-A1 | METHOD AND DEVICE FOR DETECTING NUCLEIC ACID, AND KIT | Kaneka Corporation (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| EP-1778624-B1 | TYROSINE DERIVATIVES AS PPAR-GAMMA-MODULATORS | SALVAT LAB SA (ES) | 2008-08-20 | — | — | EP | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
| EP-1778624-A1 | TYROSINE DERIVATIVES AS PPAR-GAMMA-MODULATORS | Laboratorios SALVAT, S.A. (ES) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010775-A1 | TYROSINE DERIVATIVES AS PPAR-GAMMA-MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| US-20050153408-A1 | 7-substituted-2-tetralone or bisulfite adduct is reduced microorganism (Candida) to optically active 7-substituted-2-tetralol;sulfonyl group is introduced to hydroxy group to form optically active 7-substituted-2-sulfonyloxytetralin; nitrogen substituent is introduced via ammonia; industrial scale | KANEKA CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1457570-A1 | PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | KMT2A 2852/4885MEN1 4879/4885CA2 4026/4885 |
| US-20240024238-A1 | NONCOMPETITIVE RECEPTOR-TARGETED VACCINE DELIVERY TO PLASMACYTOID DENDRITIC CELLS | HAVCR2, CD4, CD44 | KMT2A 4441/4885MEN1 4673/4885CA2 4088/4885 |
| US-12576029-B2 | Noncompetitive receptor-targeted vaccine delivery to plasmacytoid dendritic cells | DGKG, PHOSPHO1, TLR3 | KMT2A 4019/4885MEN1 4492/4885CA2 3036/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | KMT2A 2792/4885MEN1 4879/4885CA2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.